(6R,7R)-7-([(Z)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino) -8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

對本劑有感受性的細菌引起之下列感染症：支氣管炎、支氣管擴張症感染、慢性呼吸道疾患二次感染、腎孟腎炎、膀胱炎、急性攝護腺炎、淋菌性尿道炎。

Absorption
Capsules
Cmax is 17.9 mcg/mL.

Suspension
Cmax is about 15 mcg/mL. T max is about 2.6 h. AUC is about 73.7 mcg•h/mL.

Food Capsules
Tmax is increased 1.75 h. C max is decreased 18%. AUC is decreased 8%.

Suspension
Cmax is decreased 17% to 26%. AUC is decreased 12% to 17%. Take on an empty stomach.

Distribution
Vd is about 0.21 L/kg (capsules) and 0.5 L/kg (suspension).

Elimination
The t ½ is about 2.4 h. Cl is about 1.3 mL/min/kg. About 56% is excreted in the urine and 39% in the feces.

Special Populations
Renal Function Impairment
The t½ is increased and Cl decreased. Dosage adjustment is recommended.

Elderly
Drug accumulation in the plasma was increased to 40%. Dosage adjustment may be needed.